- Email: [email protected]
Abstract No. 74: Interventional oncology research: Slowing growth, limited focus, and inadequate funding
Materials and Methods: MCA-RH7777 cells (106 cells) were implanted in the left hepatic lobe of rats (n⫽21) and tumor formation was confirmed with 18F-FDG positron emission tomography (PET) 14 days later. Tumor-bearing rats were administered 109 pfu of Ad-Survivin-TRAIL-FL either intravenously (IV; n⫽7) or IT (n⫽8). Control vector groups received 109 pfu of adenovirus encoding a CMV promoter and FL (IV; n⫽3, IT; n⫽3). 24 hours post-viral delivery, bioluminescence imaging (BLI) was performed to evaluate the location and level of gene expression. 18FFDG-PET imaging was performed on the day of and on day 4, 7 post-viral delivery to evaluate therapeutic efficacy.
Conclusion: After a period of rapid growth, global publication growth in interventional oncology is slowing, raising questions about its sustainability. Interventional oncology research has focused heavily on liver cancer, with relatively little emphasis on other tumors. The US focuses on review articles, and its relative contribution has steadily declined. Asian nations focus on clinical trials and exhibit steady growth. The NIH funding of US interventional oncology research has been relatively poor.
Results: With IV delivery, BLI at 24 hours post-viral delivery showed no measurable signal from all tumors, but PET on day 7 demonstrated superior therapeutic efficacy compared with the control IV group [3.5⫾0.58 (tumor/liver ratio) vs 6.0⫾0.71, p⫽0.02]. In contrast, IT delivery resulted in positive BLI signal from all tumors (1.74x105⫾1.07x104 p/s/cm2/sr), and day 7 PET demonstrated superior efficacy compared with control IT group (2.4⫾0.50 vs 5.4⫾0.78, p⫽0.01). Importantly, superior therapeutic efficacy was observed with IT delivery compared to IV delivery of Ad-Survivin-TRAIL-FL (day 7 PET: 2.4⫾0.50 vs 3.5⫾0.58, p⫽0.003).
An examination of the inventiveness of the Society of Interventional Radiology membership K.J. Murphy1,2, R. Mandani1,2; 1Department of Medical Imaging, University of Toronto, Toronto, ON, Canada; 2 Faculty of Law, Queen’s University, Kingston, ON, Canada.
Conclusion: Though IV delivery of Ad-Survivin-TRAIL-FL showed a therapeutic effect, IT injection demonstrated superior transduction efficiency and therapeutic efficacy. Thus local delivery is a promising approach for amplifying the tumor-specific kill of transcriptionally-targeted therapeutic vectors and this combination of strategies may one day lead to improved therapeutic outcome of patients. 10:51 AM
Abstract No. 74
Interventional oncology research: Slowing growth, limited focus, and inadequate funding D.S. Chow, M.W. Itagaki; University of California Los Angeles, Los Angeles, CA. Purpose: The purpose of this study was to retrospectively examine the characteristics and trends of interventional oncology research. Materials and Methods: Interventional oncology articles published from 1996 to 2008 were identified in the National Library of Medicine’s MEDLINE database. Country of origin, article methodology, and study topic were recorded. Growth was analyzed using linear and nonlinear regression with P ⱕ .05 for significance. Results: A total of 1,887 journal articles were identified, of which 563 (29.8%) originated from the US, 255 (13.5%) from Japan and 174 (9.2%) from Italy. Global publications grew from 4 articles in 1996 to 317 in 2008 with a sigmoid pattern (predicted maximum 298.5 articles/year, P ⬍.001). Growth for the US was sigmoid (max 75.2 articles/year; P ⬍.001) and was linear in Japan, Italy, and China (growth 4.7 articles/year, P ⬍.001; 2.5 articles/year, P ⬍.001; 3.3 articles/year, P ⬍.001, respectively). The US fraction of world research shrank from 42.9% in 1998 to 24.6% in 2008. The US produced twice as many review articles as clinical trials. Japan and China published 4.3 and 6.7 times as many clinical trials as review articles, respectively. National Institutes of Health (NIH) funded articles numbered 63 (11.2% of US). Liver cancer articles numbered 1093 (57.9%), kidney 252 (13.4%), lung 164 (8.7%), and colorectal 123 (6.5%). S30
11:03 AM
Abstract No. 75
Purpose: The purpose of this research was to cross reference the membership of the Society of Interventional radiology with patent fillings and applications at the US patent and trademark office (USPTO) and at the international patent filling body, the PCT. The aim was to find a metric of the inventiveness of the membership and sense of the contribution it has made to the creation of the field of image guided therapy. Materials and Methods: We cross-referenced, name-byname, the membership directory of the SIR with the filing sat the USPTO and PCT. We tabulated and differentiated issued patents and patent applications. To ensure that the names of the members were the same as the inventors who filed we cross-referenced the mailing addresses with the filing address of record. Results: 6200 names and addresses listed in the membership directory were queried at the USPTO and PCT. 2492 patents and applications were found. There were 622 issued patents and 938 patent applications at the USPTO. There were 629 issued patents and 303 patent applications at the PCT. 211 members filed one patent, 175 members filed between 2 and 10 patents 29 filled between 10 and 20 patents, 10 filled between 20 and 30 patents, 14 filled between 30 and 170 patents . After 1995 there was a marked and sustained increase in patent fillings. MDs far out numbered PhDs. Listing of University affiliation did not exceed non academic membership fillings. By nationality US patents and applications (1617) were followed by European (629), Japanese (94) Korean (28) Czech (26), Australian (19) and Canadian(16). Conclusion: The inventiveness and creativity of the SIR membership far surpassed our expectations. The contribution of the members to the filed is striking. Membership demographics indicates that clinical challenges and daily work are the greatest sources of innovation. 11:15 AM
Abstract No. 76
Intra-arterial hepatic chemotherapy: A comparison of percutaneous versus surgical implantation of port catheters F. Deschamps, D. Elias, D. Goere, T. de Baere; Gustave Roussy Institute, Villejuif, France. Purpose: To retrospectively compare safety and efficacy of percutaneous and surgical implantation of ports for intraarterial hepatic chemotherapy.
Conclusion: After a period of rapid growth, global publication growth in interventional oncology is slowing, raising questions about its sustainability. Interventional oncology research has focused heavily on liver cancer, with relatively little emphasis on other tumors. The US focuses on review articles, and its relative contribution has steadily declined. Asian nations focus on clinical trials and exhibit steady growth. The NIH funding of US interventional oncology research has been relatively poor.
Results: With IV delivery, BLI at 24 hours post-viral delivery showed no measurable signal from all tumors, but PET on day 7 demonstrated superior therapeutic efficacy compared with the control IV group [3.5⫾0.58 (tumor/liver ratio) vs 6.0⫾0.71, p⫽0.02]. In contrast, IT delivery resulted in positive BLI signal from all tumors (1.74x105⫾1.07x104 p/s/cm2/sr), and day 7 PET demonstrated superior efficacy compared with control IT group (2.4⫾0.50 vs 5.4⫾0.78, p⫽0.01). Importantly, superior therapeutic efficacy was observed with IT delivery compared to IV delivery of Ad-Survivin-TRAIL-FL (day 7 PET: 2.4⫾0.50 vs 3.5⫾0.58, p⫽0.003).
An examination of the inventiveness of the Society of Interventional Radiology membership K.J. Murphy1,2, R. Mandani1,2; 1Department of Medical Imaging, University of Toronto, Toronto, ON, Canada; 2 Faculty of Law, Queen’s University, Kingston, ON, Canada.
Conclusion: Though IV delivery of Ad-Survivin-TRAIL-FL showed a therapeutic effect, IT injection demonstrated superior transduction efficiency and therapeutic efficacy. Thus local delivery is a promising approach for amplifying the tumor-specific kill of transcriptionally-targeted therapeutic vectors and this combination of strategies may one day lead to improved therapeutic outcome of patients. 10:51 AM
Abstract No. 74
Interventional oncology research: Slowing growth, limited focus, and inadequate funding D.S. Chow, M.W. Itagaki; University of California Los Angeles, Los Angeles, CA. Purpose: The purpose of this study was to retrospectively examine the characteristics and trends of interventional oncology research. Materials and Methods: Interventional oncology articles published from 1996 to 2008 were identified in the National Library of Medicine’s MEDLINE database. Country of origin, article methodology, and study topic were recorded. Growth was analyzed using linear and nonlinear regression with P ⱕ .05 for significance. Results: A total of 1,887 journal articles were identified, of which 563 (29.8%) originated from the US, 255 (13.5%) from Japan and 174 (9.2%) from Italy. Global publications grew from 4 articles in 1996 to 317 in 2008 with a sigmoid pattern (predicted maximum 298.5 articles/year, P ⬍.001). Growth for the US was sigmoid (max 75.2 articles/year; P ⬍.001) and was linear in Japan, Italy, and China (growth 4.7 articles/year, P ⬍.001; 2.5 articles/year, P ⬍.001; 3.3 articles/year, P ⬍.001, respectively). The US fraction of world research shrank from 42.9% in 1998 to 24.6% in 2008. The US produced twice as many review articles as clinical trials. Japan and China published 4.3 and 6.7 times as many clinical trials as review articles, respectively. National Institutes of Health (NIH) funded articles numbered 63 (11.2% of US). Liver cancer articles numbered 1093 (57.9%), kidney 252 (13.4%), lung 164 (8.7%), and colorectal 123 (6.5%). S30
11:03 AM
Abstract No. 75
Purpose: The purpose of this research was to cross reference the membership of the Society of Interventional radiology with patent fillings and applications at the US patent and trademark office (USPTO) and at the international patent filling body, the PCT. The aim was to find a metric of the inventiveness of the membership and sense of the contribution it has made to the creation of the field of image guided therapy. Materials and Methods: We cross-referenced, name-byname, the membership directory of the SIR with the filing sat the USPTO and PCT. We tabulated and differentiated issued patents and patent applications. To ensure that the names of the members were the same as the inventors who filed we cross-referenced the mailing addresses with the filing address of record. Results: 6200 names and addresses listed in the membership directory were queried at the USPTO and PCT. 2492 patents and applications were found. There were 622 issued patents and 938 patent applications at the USPTO. There were 629 issued patents and 303 patent applications at the PCT. 211 members filed one patent, 175 members filed between 2 and 10 patents 29 filled between 10 and 20 patents, 10 filled between 20 and 30 patents, 14 filled between 30 and 170 patents . After 1995 there was a marked and sustained increase in patent fillings. MDs far out numbered PhDs. Listing of University affiliation did not exceed non academic membership fillings. By nationality US patents and applications (1617) were followed by European (629), Japanese (94) Korean (28) Czech (26), Australian (19) and Canadian(16). Conclusion: The inventiveness and creativity of the SIR membership far surpassed our expectations. The contribution of the members to the filed is striking. Membership demographics indicates that clinical challenges and daily work are the greatest sources of innovation. 11:15 AM
Abstract No. 76
Intra-arterial hepatic chemotherapy: A comparison of percutaneous versus surgical implantation of port catheters F. Deschamps, D. Elias, D. Goere, T. de Baere; Gustave Roussy Institute, Villejuif, France. Purpose: To retrospectively compare safety and efficacy of percutaneous and surgical implantation of ports for intraarterial hepatic chemotherapy.